Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is operating in a highly competitive and fragmented segment of Pharma products. It posted average financial performance for the reported periods with boosted bottom line for FY24. Based on FY24 earnings, the issue appears fully priced. Well-informed investors may park moderate funds for the long term rewards. Read detail review...
Medicamen Organics Limited peer comparison with similar listed entities. (As on March 31, 2024)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Medicamen Organics Limited | 3.18 | 3.18 | 17.66 | 15.83 | 1.93 | ||
| Brooks Laboratories Ltd. | -12.57 | -12.57 | 30.10 | 10.60 | -28.26 | 4.43 | |
| Cian Healthcare Ltd | 0.43 | 0.43 | 22.40 | 53.84 | 1.75 | 1.03 | |
| Zenotech Laboratories Ltd. | 1.90 | 1.90 | 14.20 | 38.76 | 14.08 | 5.19 |
Notes:
Medicamen Organics IPO Reviews, analysis and views by popular members. Read Medicamen Organics Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP